Upstream completes analysis of FAST-TRAC cohort
Upstream has now completed analysis after testing 1,500 chest pain patients from the US and Switzerland, the FAST-TRAC cohort.
This analysis demonstrates 90% sensitivity, 63% specificity and 98.5% negative predictive value to diagnose unstable angina, representing a 29% relative improvement in specificity compared to current triage protocols.
Detecting at-risk heart attack patients, a step closer with $2m investment
Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.
Upstream commences testing Marker C on the APACE cohort
The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.